

The immunohistochemical expression of D-type cyclins in Endometrial Stromal Sarcomas.

Yulia Humrye^{1,2}, Mridula Chopra^{2,3}, Chit Cheng Yeoh⁴, Francis John Edward Gardner⁵, Siavash Rahimi⁶

¹ Biomedical Science, University of Chichester; ² School of Medicine, Pharmacy and Biomedical Sciences, University of Portsmouth; ³ Institute of Optimum Nutrition; ⁴ Portsmouth Hospitals University NHS Trust; ⁵ Oxford University Hospitals NHS Foundation Trust ; ⁶ Princess Elizabeth Hospital, Pathology, Saint Martin, Guernsey.

Introduction


Histological differentiation of endometrial stromal sarcomas (ESS) into low-grade (LG) and high-grade (HG) entities utilises cyclin D1 [1]. The cyclin D family also includes D2 and D3; however, diagnostic practice has not yet exploited them. Cyclin D1 can be a prognostic factor for predicting worse survival in patients with carcinomas [2]. Limited research has searched for the relationship between cyclin D family markers and survival in ESS patients. This study evaluated the prevalence of ESS in England, UK, clinicopathological and prognostic characteristics, including the immunohistochemical (IHC) expression of cyclin D1, D2, D3.

Materials & Methods

The Get Data Out reported in England between 2013 and 2020 was reviewed [3]. The pathology database of a general hospital was searched for primary uterine ESS cases. Using the morphological features, cases were categorised into LG (Fig.1) and HG (Fig.2) and tested with IHC (Fig. 3-4).

Results

The cumulative prevalence of ESS cases ranged between 66-98 per year (IR 0.119–0.174) (Tab.1). Thirteen cases (morphologically, 7 LG and 6 HG) showed cyclin D1 and D2 correlation (p-value < .001). Cyclin D3 correlated with the LVSI (p-value 0.049) in LG cases. The overall survival (OS) between LG and HG was significant (p-value 0.022), but not the disease-free survival (DFS) (Fig. 5-7).




Discussion / Conclusion

ESS are ultra-rare tumours with a low incidence rate. Both cyclin D1 and D2 negative cases had a longer DFS and OS, compared to positive cases, regardless of morphological findings. Hence, Cyclin D markers might be explored as prognostic in ESS. Positive cyclin D1 indicated a positive cyclin D2 case; therefore, either marker could aid in histopathologic examination to distinguish LG from HG ESS, given the right clinical context.

References

1. Female Genital Tumours. (2020). WHO Classification of Tumours. 5th ed; WHO Classification of Tumours Editorial Board, Eds.; IARC Publications;
2. Moradi Binabaj, M., Bahrami, A., Khazaei, M., Ryzhikov, M., Ferns, G. A., Avan, A., & Mahdi Hassanian, S. (2020). The prognostic value of cyclin D1 expression in the survival of cancer patients: A meta-analysis. Gene, 728, 144283. <https://doi.org/10.1016/j.gene.2019.144283>;
3. Detailed Statistics from the 'Get Data Out' programme. (2024). NDRS National Disease Register Service. NHS Digital. <https://www.cancerdata.nhs.uk/getdataout/data>.

Key words: ESS, HG ESS, LG ESS, cyclin D, immunohistochemistry, survival



ESS show diverse morphological appearances and a variety of cellular differentiation and histological patterns. This makes the histopathological diagnosis of these tumours difficult. IHC is frequently used to classify entities within the ESS spectrum, and it also holds potential for exploring prognostic features.




Table 1. Results of evaluating the prevalence of ESS in the UK between 2013 and 2020, as reported in the national cancer register and accessed through the Get Data Out [3].

Year	Tumour Type	Incidence	Population	Incidence rate
2013	ESS	86	53,865,817	0.16
2014	ESS	82	54,316,618	0.151
2015	ESS	86	54,786,327	0.157
2016	ESS	66	55,268,067	0.119
2017	ESS	85	55,619,430	0.153
2018	ESS	94	55,977,178	0.168
2019	ESS	98	56,286,961	0.174
2020	ESS	91	56,550,138	0.161

